Total Funding
19
37
Total FundingGrant raised
Growth Score
7 pts
Heat Score
-19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
59708
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.
Angela Scott: Chief Operating Officer & FounderPast Role: Cancer Research UK, Senior Scientific Officer- Martin Thorp: Chief Financial Officer
About the Company
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of
treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
